Strategic IP Support since 1997
Recent Insights & News
Patent or trade secret? Match your IP protection to how long the value lasts
A treatment that works once and keeps working for years is a very different commercial asset from a pill taken every day. The value is created up front. It then has to be defended for decades. That turns the patent vs trade secret question into a horizon question, and it is one every IP strategy…
The Most Likely Idea Is the Least Protectable: What AI-Assisted Innovation Means for Your Patent Strategy
Patent law only pays for outliers. Novelty and inventive step exist to screen out the expected, so a patent portfolio is, by design, a collection of exceptions. Hold that thought against new research from Harvard, Wharton, Northwestern and Columbia, published in Harvard Business Review on 14 August 2026, on what generative AI actually does inside…
Build, Buy or Licence? What Bayer’s Hybrid Wheat Deal Teaches About IP Licensing Strategy
Some assets cannot be built on any timeline a budget can shorten. When that is true, the choice is no longer build, buy or licence. It is licence, or stay out. Bayer’s move into hybrid wheat this year is a clean example, and a useful test of any IP licensing strategy. The world’s largest seed…
The Five-Year IP Roadmap Is Over: How to Build an IP Strategy for a Future You Can’t Predict
Long-lived patents, an AI-shifted landscape: why a fixed filing roadmap fails, and the three decision rules an IP strategy needs instead.
Your Patent Expiry Date Is the Wrong Number: What Loss of Exclusivity Actually Looks Like
Most boards plan around a single date. The patent expires, competitors arrive, the revenue line falls off a ledge. That model is tidy, it sits in the forecast, and for high-value products it is usually wrong. A recent analysis on DrugPatentWatch works through the loss-of-exclusivity histories of Revlimid, Humira, Eliquis and Keytruda and finds no…
